Caris Life Sciences, Inc. — Director's Dealing 2026

Feb 28, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caris Life Sciences, Inc. (CAI)
CIK: 0002019410
Period of Report: 2026-02-26

Reporting Person: CASTLEMAN PETER M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-26	Common Stock	A	5509	$20.06	Acquired	24138	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	100000	Indirect
Common Stock	10270906	Indirect

Footnotes

F1: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

F2: CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.